Allogeneic CAR T cell therapies for leukemia.
Journal
American journal of hematology
ISSN: 1096-8652
Titre abrégé: Am J Hematol
Pays: United States
ID NLM: 7610369
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
10
11
2018
revised:
21
12
2018
accepted:
08
01
2019
pubmed:
12
1
2019
medline:
9
4
2020
entrez:
12
1
2019
Statut:
ppublish
Résumé
Allogeneic chimeric antigen receptor T (CAR T) cells can offer advantages over autologous T cell therapies, including the availability of "fit" cells for production, and elimination of risks associated with inadvertent transduction of leukemic blasts. However, allogeneic T cell therapies must address HLA barriers and conventionally rely on the availability of a suitable HLA-matched donor if graft-vs-host-disease and rejection effects are to be avoided. More recently, the incorporation of additional genome editing manipulations, to disrupt T cell receptor expression and address other critical pathways have been explored. Clinical trials are underway investigating non-HLA matched T cells expressing anti-CD19 CARs for the treatment of B cell acute lymphoblastic leukemia (B-ALL) and anti-CD123 CAR for acute myeloid leukemia (AML). Such approaches continue to be refined and improved to widen accessibility and reduce the cost of T cell therapies for a wider range of conditions.
Substances chimiques
Receptors, Chimeric Antigen
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
S50-S54Subventions
Organisme : Department of Health
ID : RP-2014-05-007
Pays : United Kingdom
Organisme : National Institute for Health Research
ID : RP2014
Pays : International
Organisme : Great Ormond Street Biomedical Research Centre
Pays : International
Informations de copyright
© 2019 Wiley Periodicals, Inc.